Entities / Entity
Nippon Shinyaku.
Japanese pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 17
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Nippon Shinyaku paid AB2 Bio $30 million on July 30, 2026.Some support1 report
-
Nippon Shinyaku is funding the development of treatments for DMD, with its US subsidiary located in New Jersey.Some support1 report
-
Boston Children's Hospital, Nippon Shinyaku, and Paramus have formed a strategic partnership focused on innovative therapeutic drug development.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Nippon Shinyaku this week
News at the entities that move Nippon Shinyaku most-
New Jersey StructuralMargie Donlon and Shama Haider introduced a microplastics bill in New Jersey.Moves Nippon Shinyaku
Connections
The 5 strongest of 17, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Paramus Structural
Paramus is a wholly owned subsidiary of Nippon Shinyaku.
-
New Jersey Structural
Nippon Shinyaku operates as a subsidiary located within the jurisdiction of New Jersey.
-
DMD Structural
Nippon Shinyaku is funding the development of treatments for DMD.
-
Boston Children's Hospital Operational
Boston Children's Hospital and Nippon Shinyaku maintain a strategic partnership for innovative therapeutic drug development.
-
Kyoto Shared context
Nippon Shinyaku is headquartered in Kyoto.